Anthropic and medical-AI company OpenEvidence have partnered to bring free, AI-powered clinical decision support to physicians across roughly 100 low- and middle-income countries, Reuters reported this week. The initiative extends a platform already widely used by doctors in the U.S. and Europe into regions where access to medical literature, specialist expertise, and continuing medical education has historically been far more limited.
What OpenEvidence Actually Does
OpenEvidence is a clinical search platform that answers physicians’ medical questions by drawing on peer-reviewed research and established treatment guidelines, pulling from sources including the New England Journal of Medicine, JAMA Network, NCCN guidelines, Nature, and Cochrane reviews. The platform has already become a significant part of clinical practice in wealthier countries: it’s currently free for clinicians across the U.S. and Europe, and OpenEvidence founder and CEO Daniel Nadler told Reuters that U.S. clinicians logged 42 million consultations on the platform in August alone, estimating that several hundred million Americans will have been treated in 2026 by a doctor who used the tool to help guide care.
How the Partnership Is Structured
Under the arrangement, Anthropic supplies the underlying AI models that power OpenEvidence’s back-end infrastructure, while OpenEvidence handles adapting the platform for each region it expands into, adjusting for local disease patterns, available diagnostic tools, and realistic treatment options rather than simply porting over the version already used in wealthier health systems. The rollout covers roughly 100 countries, including Uganda, Angola, Sudan, Haiti, and Mongolia, according to a list OpenEvidence provided to Reuters. Neither company disclosed the financial terms of the arrangement.
Built and Tested With Local Health Systems
The initiative isn’t launching without groundwork. OpenEvidence said it has spent the past year working with health organizations in Rwanda and Botswana to adapt its tools for conditions considerably different from those the platform was originally built around. In Rwanda, a pilot conducted with the Rwanda Biomedical Center and the nonprofit Resolve to Save Lives involved 45 local doctors and nurses who tested the adapted tool and provided direct feedback on necessary changes.
“One hundred percent of what we are developing for these areas is designed to be context adaptive.”
— Daniel Nadler, Founder and CEO, OpenEvidence
Addressing a Real Infrastructure Gap
Unreliable electricity remains a genuine practical obstacle across many of the targeted low-resource settings, something the companies say they’ve had to account for directly in how the tool is deployed. According to Nadler, one advantage working in the platform’s favor is that most doctors in these regions still maintain access to smartphones even when their clinics face inconsistent power, meaning a mobile-first tool can reach physicians in settings where a desktop-dependent system might not.
The Question Critics Are Raising
Not every reaction has been uncritical. Independent observers have flagged a structural concern worth taking seriously: AI clinical tools trained primarily on medical evidence and treatment guidelines generated in high-income countries may not fully reflect how medicine is actually practiced in lower-resource settings, where available diagnostics, medication access, and disease prevalence can differ substantially from the conditions that evidence base was built around. That’s precisely the gap OpenEvidence says its regional adaptation work is meant to address, but the concern underscores that “context-adaptive” is a claim the platform will need to keep demonstrating in practice as it expands into markedly different healthcare environments, rather than one that’s fully proven simply by the partnership’s launch.
Part of a Broader Pattern for Anthropic in Healthcare
The OpenEvidence partnership adds to a string of healthcare-focused announcements from Anthropic this month, following the company’s drug-discovery partnership with Novo Nordisk announced just days earlier.
“The technology itself has advanced so dramatically… but the market incentives alone would not let it happen without this type of entrepreneurial, philanthropically minded work.”
— Daniela Amodei, President, Anthropic
Nadler summarized the initiative’s underlying premise more simply, telling Reuters that access to medical knowledge shouldn’t depend on geography.
What Comes Next
Neither company has published a detailed rollout timeline for how quickly the adapted platform will reach physicians across all roughly 100 targeted countries, or how OpenEvidence plans to measure whether its regional adaptations are actually holding up in the diverse clinical conditions those countries represent. For now, the initiative’s success will likely be judged less by the breadth of its country list and more by whether physicians in resource-constrained settings find the tool genuinely useful for the specific diagnostic and treatment challenges they face day to day, the same test any clinical decision-support tool ultimately has to pass regardless of how sophisticated the underlying AI model is.